In depth: Why HGS ruling will benefit biotech investment
Yesterday’s Supreme Court decision in HGS v Eli Lilly gives applicants more certainty by bringing UK law on industrial applicability into line with that applied in the EPO
In their decision, the five judges of the Supreme Court unanimously reversed the lower courts' decisions that HGS's patent for neutrokine-α was invalid as it lacked industrial application.
In doing so, they pointed to policy aims that biotech investment should...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.